TESARO (TSRO) Getting Somewhat Positive News Coverage, Study Shows

News stories about TESARO (NASDAQ:TSRO) have trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. TESARO earned a news sentiment score of 0.23 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.6797945225119 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

A number of equities analysts have issued reports on TSRO shares. Barclays started coverage on shares of TESARO in a research report on Monday, October 23rd. They issued an “equal weight” rating and a $135.00 price objective on the stock. ValuEngine cut shares of TESARO from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Jefferies Group reaffirmed a “hold” rating and set a $124.00 target price on shares of TESARO in a research note on Friday, November 3rd. HC Wainwright reaffirmed a “buy” rating and set a $158.00 target price on shares of TESARO in a research note on Thursday, October 26th. Finally, Morgan Stanley reaffirmed an “overweight” rating and set a $165.00 target price (down previously from $181.00) on shares of TESARO in a research note on Wednesday, November 8th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. TESARO has an average rating of “Buy” and an average price target of $152.64.

Shares of TESARO (TSRO) traded down $0.36 during midday trading on Thursday, hitting $75.99. 471,100 shares of the stock traded hands, compared to its average volume of 934,814. The company has a market capitalization of $3,990.00, a P/E ratio of -9.01 and a beta of 1.51. TESARO has a 52-week low of $73.97 and a 52-week high of $192.94. The company has a current ratio of 4.73, a quick ratio of 4.35 and a debt-to-equity ratio of 0.34.

TESARO (NASDAQ:TSRO) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.69. TESARO had a negative net margin of 251.22% and a negative return on equity of 93.39%. The firm had revenue of $142.77 million for the quarter, compared to the consensus estimate of $130.57 million. During the same quarter in the prior year, the firm posted ($1.72) earnings per share. The business’s revenue was up 740.3% on a year-over-year basis. equities research analysts forecast that TESARO will post -8.19 earnings per share for the current year.

In other news, SVP Martin H. Jr. Huber sold 829 shares of the business’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $85.24, for a total transaction of $70,663.96. Following the completion of the transaction, the senior vice president now directly owns 8,101 shares of the company’s stock, valued at $690,529.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 34.60% of the stock is owned by insiders.

WARNING: This piece of content was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://stocknewstimes.com/2018/01/11/tesaro-tsro-given-media-impact-score-of-0-23-2.html.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Insider Buying and Selling by Quarter for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply